J David Prologo1, Matthew Passalacqua, Indravadan Patel, Nathan Bohnert, David J Corn. 1. Emory University Hospital, Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image-Guided Medicine, 1364 Clifton Road, NE Suite D112, Atlanta, GA, 30322, USA, jdprologo@hotmail.com.
Abstract
PURPOSE: The role of image-guided thermal ablation techniques for the nonoperative local management of painful osseous metastatic disease has expanded during recent years, and several advantages of cryoablation in this setting have emerged. The purpose of this study is to retrospectively evaluate and report a single-center experience of CT-guided percutaneous cryoablation in the setting of painful musculoskeletal metastatic disease. METHODS: This study was approved by the institutional review board and is compliant with the Health Insurance Portability and Accountability Act. Electronic medical records of all patients who underwent percutaneous image-guided palliative cryoablation at our institution were reviewed (n = 61). An intent-to-treat analysis was performed. Records were reviewed for demographic data and anatomical data, primary tumor type, procedure details, and outcome-including change in analgesic requirements (expressed as morphine equivalent dosages), pain scores (utilizing the clinically implemented visual analog scale), subsequent therapies (including radiation and/or surgery), and complications during the 24 h following the procedure and at 3 months. Patients were excluded (n = 7) if data were not retrospectively identifiable at the defined time points. RESULTS: Fifty-four tumors were ablated in 50 patients. There were statistically significant decreases in the median VAS score and narcotic usage at both 24 h and 3 months (p < 0.000). Six patients (11%) incurred complications related to their therapy. Two patients had no relief at 24 h, of which both reported worsened pain at 3 months. One patient had initial relief but symptom recurrence at 3 months. Four patients went on to have radiation therapy of the ablation site at some point following the procedure. CONCLUSIONS: CT-guided cryoablation is a safe, effective, reproducible procedural option for the nonoperative local treatment of painful musculoskeletal metastatic disease.
PURPOSE: The role of image-guided thermal ablation techniques for the nonoperative local management of painful osseous metastatic disease has expanded during recent years, and several advantages of cryoablation in this setting have emerged. The purpose of this study is to retrospectively evaluate and report a single-center experience of CT-guided percutaneous cryoablation in the setting of painful musculoskeletal metastatic disease. METHODS: This study was approved by the institutional review board and is compliant with the Health Insurance Portability and Accountability Act. Electronic medical records of all patients who underwent percutaneous image-guided palliative cryoablation at our institution were reviewed (n = 61). An intent-to-treat analysis was performed. Records were reviewed for demographic data and anatomical data, primary tumor type, procedure details, and outcome-including change in analgesic requirements (expressed as morphine equivalent dosages), pain scores (utilizing the clinically implemented visual analog scale), subsequent therapies (including radiation and/or surgery), and complications during the 24 h following the procedure and at 3 months. Patients were excluded (n = 7) if data were not retrospectively identifiable at the defined time points. RESULTS: Fifty-four tumors were ablated in 50 patients. There were statistically significant decreases in the median VAS score and narcotic usage at both 24 h and 3 months (p < 0.000). Six patients (11%) incurred complications related to their therapy. Two patients had no relief at 24 h, of which both reported worsened pain at 3 months. One patient had initial relief but symptom recurrence at 3 months. Four patients went on to have radiation therapy of the ablation site at some point following the procedure. CONCLUSIONS: CT-guided cryoablation is a safe, effective, reproducible procedural option for the nonoperative local treatment of painful musculoskeletal metastatic disease.
Authors: Juan Miguel Jimenez-Andrade; William G Mantyh; Aaron P Bloom; Alice S Ferng; Christopher P Geffre; Patrick W Mantyh Journal: Ann N Y Acad Sci Date: 2010-06 Impact factor: 5.691
Authors: Hyun J Bang; Peter J Littrup; Brandt P Currier; Dylan J Goodrich; Hussein D Aoun; Lydia C Klein; Jarret C Kuo; Lance K Heilbrun; Shirish Gadgeel; Allen C Goodman Journal: J Vasc Interv Radiol Date: 2012-06 Impact factor: 3.464
Authors: Paul G Thacker; Matthew R Callstrom; Timothy B Curry; Jayawant N Mandrekar; Thomas D Atwell; Matthew P Goetz; Joseph Rubin Journal: AJR Am J Roentgenol Date: 2011-08 Impact factor: 3.959
Authors: Bernd Wegener; Marcus Schlemmer; Joachim Stemmler; Volkmar Jansson; Hans Roland Dürr; Matthias F Pietschmann Journal: BMC Musculoskelet Disord Date: 2012-11-27 Impact factor: 2.362
Authors: Roberto Luigi Cazzato; Julien Garnon; Nitin Ramamurthy; Guillaume Koch; Georgia Tsoumakidou; Jean Caudrelier; Francesco Arrigoni; Luigi Zugaro; Antonio Barile; Carlo Masciocchi; Afshin Gangi Journal: Med Oncol Date: 2016-11-11 Impact factor: 3.064
Authors: Jack W Jennings; J David Prologo; Julien Garnon; Afshin Gangi; Xavier Buy; Jean Palussière; A Nicholas Kurup; Matthew Callstrom; Scott Genshaft; Fereidoun Abtin; Ambrose J Huang; Jason Iannuccilli; Frank Pilleul; Charles Mastier; Peter J Littrup; Thierry de Baère; Frédéric Deschamps Journal: Radiol Imaging Cancer Date: 2021-02-12
Authors: Francesco Arrigoni; Giampaolo Bianchi; Francesco Formiconi; Pierpaolo Palumbo; Luigi Zugaro; Giovanni Luca Gravina; Antonio Barile; Carlo Masciocchi Journal: Radiol Med Date: 2021-12-10 Impact factor: 3.469